Prince Edward Island Pharmacy Board, Home Page

Prince Edward Island Pharmacy Board

Regulating the practice of pharmacy in the province so as to promote a high standard and safeguard the welfare of the public with regard to pharmaceutical service.

Useful Links

NEWS & EVENTS

The Prince Edward Island Pharmacy Board has a position open for 8 weeks this summer for a (pharmacy) student to assist with a review of policies and guidelines and updating them on our website (www.pepharmacists.ca). There will be other administrative duties as well. The position is full-time (40 hrs per week at $11/hr) and available starting May 13, 2013 although starting date is negotiable . Location: PEI Pharmacy Board, Crapaud. If you are interested in applying for the job, please forward your resume to the Registrar at nauld@pepharmacists.ca

Jurisprudence Exam

The spring sitting of the PEI Jurisprudence Exam will be held June 19th, 2013 from 9:00 to 11:00 in the North Corridor classroom at the QEH. Forward an application by Friday June 14th, 2013. See link below for application.

Jurisprudence Application

PEBC has revised the deadline for the PEBC Pharmacy Technician Evaluating Exam to December 31st 2018

The PEIPB approved the Cold Chain Policy which will come into effect in June 2013. Select the link below to view the policy:

Cold Chain Policy 2013

SAFETY ADVISORIES

Health Canada RSS - MedEffect Canada - Advisories and Recalls for Health Professionals

Stay informed on new safety information for health professionals related to marketed health products. This information helps health professionals and their patients to make informed decisions about the use of therapeutic products.

05/14/2013

Notices of advisories and recalls for health professionals are now available under a different RSS Feed

Advisories and recalls for health professionals are now available as a new RSS Feed with a new URL link. Please subscribe to this new RSS Feed titled "Healthy Canadians - Recalls and Safety Alerts - MedEffect Canada - For Health Professionals" to continue to receive notices about MedEffect Canada advisories and recalls for health professionals.

02/05/2013

Health Canada to review safety of drug Diane-35

Health Canada is currently conducting a review of all available safety information on the drug Diane-35. Health Canada has been monitoring the safety of Diane-35 on an ongoing basis, as it does for all drugs on the market. The Department is aware of the decision by France to suspend the marketing authorization of Diane-35 within the next three months.

02/01/2013

Cough and Cold Products Recalled Due to Defective Caps: May Cause Serious Harm to Children

Health Canada is advising Canadians that Novartis Consumer Health Canada Inc. is conducting a voluntary recall of 17 products as the child resistant mechanism of the bottle cap can fail. As a result, children may be able to open the bottle and ingest the product. The ingredients of the affected products may be harmful to children and as such, ingestion of these products may cause serious adverse health consequences, including death.

01/24/2013

New statins labeling update: Risk of increased blood sugar levels and diabetes

Health Canada is informing Canadians of a labelling update for all cholesterol-lowering drugs (also known as statins) regarding the risk of increased blood sugar levels and a small increased risk of diabetes among patients already at risk for the disease.

01/21/2013

New Labelling Information for all Botulinum Toxin Products: Botox/Botox Cosmetic, Dysport, Xeomin/Xeomin Cosmetic and Myobloc

In order to help prevent medication errors with the use of botulinum toxin products currently available on the Canadian market, Health Canada will be requesting that all manufacturers of these products revise their product labels to reflect that each product has its own individual potency and as such, is not interchangeable with other botulinum products.

12/24/2012

Pradaxa (dabigatran, previously called Pradax): not to be used in patients with artificial heart valves

Health Canada is advising health care professionals and the public that, based on new information, the blood-thinning drug Pradaxa is not to be used in patients with artificial heart valves (also known as prosthetic heart valves) due to the risk of strokes, bleeding, heart attacks, and blood clots forming on the artificial heart valves.

12/21/2012

Pradaxa/Pradax (dabigatran etexilate) - New Contraindication in Patients with Artificial Heart Valves Requiring Anticoagulant Treatment Due to their Valvular Status

12/21/2012

Pradaxa/Pradax (dabigatran etexilate) - New Contraindication in Patients with Prosthetic Heart Valves Requiring Anticoagulant Treatment Due to their Valvular Status

12/06/2012

Health Canada Suspends Licence of Chemical Testing Laboratory For Providing Falsified Results

Health Canada has suspended the Establishment Licence of Chemi Pharmaceutical Inc. of Mississauga, Ont., after uncovering falsified testing results during the course of an inspection. Health Canada is verifying the nature and use of testing done by Chemi Pharmaceutical Inc. with the company’s customers. Our survey of clients to date indicates that only a portion of the company’s work involved testing of final products before they entered the Canadian market.

11/28/2012

Thermography Machines not Authorized to Screen for Breast Cancer

Health Canada is advising Canadians and health care practitioners that no thermography (thermal imaging) machines have been approved to screen for breast cancer in Canada. Health Canada is not aware of any clinical evidence that thermography can be used effectively as a screening technique for the early detection of breast cancer. As such, it may present a potential risk to women relying on the results.

11/21/2012

PROLIA (denosumab) - Association with the Risk of Atypical Femoral Fractures

Cases of atypical femoral fractures associated with PROLIA (denosumab) treatment have been reported in patients participating in an ongoing clinical trial involving postmenopausal women with osteoporosis.

11/13/2012

Zocor (simvastatin) - New Safety Recommendations on Dosage Associated with the Increased Risk of Muscle Problems

The Canadian Product Monograph has been updated to reflect the increased risk of certain muscular problems (myopathy/rhabdomyolysis) when taking Zocor at a high dose or with certain foods/medications. Healthcare professionals and the public are being advised of this risk.

11/09/2012

AGRIFLU and FLUAD - Health Canada Lifts the Suspension of Distribution of these Seasonal Flu Vaccines

Novartis Pharmaceuticals Canada Inc., in collaboration with Health Canada, would like to inform you that the review of the safety information for AGRIFLU and FLUAD is now complete and Health Canada has released the two seasonal flu vaccines for immediate use.

11/08/2012

Expanded Recall of X3 Clean Alcohol-Free Foaming Hand Sanitizer

Avmor Ltd. has expanded its recall of products to include four additional lots of the product X3 Clean Alcohol-Free Foaming Hand Sanitizer (Benzalkonium chloride 0.13%). The X3 product was originally recalled last month as a precautionary measure following the recall of another Avmor product, Antimicrobial Foaming Hand Soap (Triclosan 0.3%), because of microbial contamination.

11/07/2012

Riata and Riata ST Silicone Endocardial Defibrillation Leads – Safety Recommendations Regarding Lead Insulation Abrasion

St. Jude Medical Inc., in collaboration with Health Canada, is providing this letter to re-iterate safety information and provide updated patient care resources and recommendations regarding insulation abrasion in Riata and Riata ST defibrillation leads.